Yenealem Temesgen‐Oyelakin

机构：National Institute of Arthritis and Musculoskeletal and Skin Diseases

发表论文 13 篇 · 总被引 546 次 · h-index 8

代表论文

• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus (2021 · Nature Communications · 被引 200)
• Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus (2018 · JCI Insight · 被引 187)
• Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus (2018 · Arthritis & Rheumatology · 被引 63)
• Association of lipoprotein subfractions and glycoprotein acetylation with coronary plaque burden in SLE (2019 · Lupus Science & Medicine · 被引 27)
• Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus (2022 · Annals of the Rheumatic Diseases · 被引 25)
• The Aconitate Decarboxylase 1/Itaconate Pathway Modulates Immune Dysregulation and Associates with Cardiovascular Disease Markers and Disease Activity in Systemic Lupus Erythematosus (2024 · The Journal of Immunology · 被引 16)